CSPI warns FDA advisers back peptides agency scientists rejected
The consumer group says newly appointed advisers with alleged ties to the peptide market are pushing to legitimize compounds FDA reviewers had turned down.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 16 06:07 ETSource: Nutrition Insight
The wire
- 01The Center for Science in the Public Interest criticized the Trump administration's move to widen consumer access to peptides, saying new FDA advisers went against agency scientists' recommendations.
- 02Any loosening of FDA's stance would directly affect which peptides 503A and 503B pharmacies can compound and what telehealth sellers may lawfully offer.
- 03CSPI's allegations about adviser conflicts are not independently verified, and no final FDA policy text or list has been issued.
From the source
Read at nutritioninsight.comFDA panel recommends peptides its own scientists rejected, CSPI warns
HMOs and precision proteins push infant formula closer to breast milk
